Accelerant Holdings (ARX) agrees to $20.25-per-share Thoma Bravo buyout after strong Q2
Rhea-AI Filing Summary
Accelerant Holdings entered into a definitive agreement to be acquired by Thoma Bravo in an all-cash Merger valuing the company at over $4 billion. Class A and Class B shareholders will receive $20.25 per share, a 49% premium to the August 12, 2026 closing price. Entities affiliated with Altamont Capital Partners holding approximately 82% of outstanding voting rights agreed to vote in favor, and the deal is expected to close in the first half of 2027, subject to shareholder and regulatory approvals. If closing is delayed by certain insurance approvals, a ticking fee of 6% per annum will accrue for a specified period. For the quarter ended June 30, 2026, Accelerant reported total revenues of $356.9 million and net income of $80.0 million. Exchange Written Premium reached $1,322.3 million, with a 23% growth rate and trailing twelve months premiums of $4.6 billion. Adjusted EBITDA was $93.1 million with a 31% adjusted EBITDA margin, and adjusted net income was $70.0 million. Operating cash flow for the first six months of 2026 was $(90.0) million, and cash, cash equivalents and restricted cash totaled $1,656.3 million at June 30, 2026. The company cancelled its earnings call and is not providing 2026 guidance due to the pending transaction.
Positive
- Take-private at significant premium: Thoma Bravo will acquire Accelerant for $20.25 per share in cash, a 49% premium to the August 12, 2026 closing price, with an enterprise value of more than $4 billion.
- Strong Q2 2026 profitability: Net income was $80.0 million versus $13.1 million a year earlier, and adjusted EBITDA rose to $93.1 million with a 31% margin, indicating materially higher earnings.
- Robust revenue and premium growth: Q2 2026 total revenues reached $356.9 million compared with $219.1 million in Q2 2025, while Exchange Written Premium grew 23% year-over-year to $1,322.3 million.
- Major shareholder support: Entities affiliated with Altamont Capital Partners, holding roughly 82% of outstanding voting rights, agreed to vote their shares in favor of the Merger, reducing execution risk.
- Potential incremental consideration: If closing is delayed by certain insurance regulatory approvals, shareholders receive a 6% per annum ticking fee for a specified period, enhancing economics if timing extends.
Negative
- Negative operating cash flow: Net cash used in operating activities for the first six months of 2026 was $(90.0) million, compared with $309.3 million provided in the prior-year period, signaling a material swing in cash generation.
- Merger execution and regulatory risks: Completion of the Thoma Bravo acquisition depends on shareholder approval and multiple regulatory approvals, and the company cites risks that the Merger may not be completed or could be delayed.
- No guidance and cancelled call: The company cancelled its Q2 2026 earnings conference call and will not provide guidance for Q3 or full-year 2026 due to the pending transaction, reducing forward-looking visibility.
Filing Explained
The merger remains proposed: a proxy statement and any required Schedule 13E-3 still precede the shareholder vote and regulatory approvals.
The proposed merger has not closed or begun proxy solicitation, so Accelerant’s Class A common shares remain listed on the NYSE while the shareholder vote and required regulatory approvals are pending.
The company intends to file a proxy statement for a special shareholder meeting and may file a Schedule 13E-3 if required; those later documents, rather than this communication, are expected to provide fuller merger details and information about participants’ interests.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
ticking fee financial
Schedule 13E-3 regulatory
special committee regulatory
non-GAAP financial measures financial
Earnings Snapshot
The company stated it will not provide guidance for the third quarter of 2026 or the full year 2026 due to the pending Thoma Bravo transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.